Management of Graves' Hyperthyroidism: More Than a Century of Progression

被引:2
|
作者
Abdi, Hengameh [1 ]
Amouzegar, Atieh [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Endocrine Res Ctr, Res Inst Endocrine Sci, Tehran, Iran
关键词
Hyperthyroidism; Surgery; Graves' Disease; Radioiodine; Antithyroid Drug; AMERICAN THYROID ASSOCIATION; ANTITHYROID DRUG-THERAPY; RADIOIODINE TREATMENT; CANCER-MORTALITY; I-131; THERAPY; FOLLOW-UP; DISEASE; OPHTHALMOPATHY; GUIDELINES; DIAGNOSIS;
D O I
10.5812/ijem.103943
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: There are three therapeutic modalities for the management of Graves' disease (GD), including thyroid surgery, radioactive iodine (RAI), and antithyroid drugs (ATDs). We aimed to briefly review the history of these treatment strategies and their advantages and disadvantages. Evidence Acquisition: We searched PubMed for English language articles using pertinent search terms. Results: Each treatment modality for GD is accompanied by several advantages and disadvantages. Nowadays, ATDs are the most commonly prescribed therapy for GD worldwide. The lack of well-designed, large RCTs comparing three different treatments for hyperthyroidism concerning various short-term and long-term outcomes has led to remarkable uncertainty in the preference of each of these treatments, as is evident in relevant guidelines from different societies. Recently, the efficacy and safety of long-term use of ATDs have been documented. Conclusions: Pros and cons of each therapeutic modality for Graves' hyperthyroidism should be taken into account during the physician-patient discussion to select the primary treatment. Considering recent data about the long-term efficacy and safety of ATDs, it seems that the appropriate selection of Graves' patients for long-term ATD therapy can be a new avenue in the treatment and even cure of GD.
引用
收藏
页数:6
相关论文
共 50 条
  • [11] Tremelimumab-Induced Graves Hyperthyroidism
    Gan, Earn H.
    Mitchell, Anna L.
    Plummer, Ruth
    Pearce, Simon
    Perros, Petros
    EUROPEAN THYROID JOURNAL, 2017, 6 (03) : 167 - 170
  • [12] An update on the medical treatment of Graves' hyperthyroidism
    Marino, Michele
    Latrofa, Francesco
    Menconi, Francesca
    Chiovato, Luca
    Vitti, Paolo
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2014, 37 (11): : 1041 - 1048
  • [13] Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism
    Abbara, Ali
    Clarke, Sophie A.
    Brewster, Rosalind
    Simonnard, Alexia
    Eng, Pei Chia
    Phylactou, Maria
    Papadopoulou, Deborah
    Izzi-Engbeaya, Chioma
    Sam, Amir H.
    Wernig, Florian
    Jonauskyte, Eliza
    Comninos, Alexander N.
    Meeran, Karim
    Kelsey, Tom W.
    Dhillo, Waljit S.
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [14] Perspectives in pharmacological management of Graves' hyperthyroidism and orbitopathy
    Bartalena, Luigi
    Lai, Adriana
    Tanda, Maria Laura
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2008, 4 (03) : 321 - 329
  • [15] A 2023 International Survey of Clinical Practice Patterns in the Management of Graves Disease: A Decade of Change
    Villagelin, Danilo
    Cooper, David S.
    Burch, Henry B.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 109 (11) : 2956 - 2966
  • [16] Long-term follow-up result of antithyroid drug treatment of Graves' hyperthyroidism in a large cohort
    Jin, Meihua
    Jang, Ahreum
    Kim, Chae A.
    Kim, Tae Young
    Kim, Won Bae
    Shong, Young Kee
    Jeon, Min Ji
    Kim, Won Gu
    EUROPEAN THYROID JOURNAL, 2023, 12 (02)
  • [17] Relapse following antithyroid drug therapy for Graves' hyperthyroidism
    Laurberg, Peter
    Krejbjerg, Anne
    Andersen, Stine Linding
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2014, 21 (05) : 415 - 421
  • [18] Total Thyroidectomy as Primary Definitive Treatment for Graves' Hyperthyroidism
    Snyder, Samuel
    Govednik, Cara
    Lairmore, Terry
    Jiang, Da-Shu
    Song, Juhee
    AMERICAN SURGEON, 2013, 79 (12) : 1283 - 1288
  • [19] An update on the pharmacological management of hyperthyroidism due to Graves' disease
    Bartalena, L
    Tanda, ML
    Bogazzi, F
    Piantanida, E
    Lai, A
    Martino, E
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 851 - 861